[Case reports of use of TS-1 for second/third-line chemotherapy for advanced colorectal carcinoma].
The usefulness of TS-1 as second/third-line therapy was evaluated in 7 patients with stage IIIb/IV colorectal cancer in whom the response to prior 5-FU/l-LV+CPT-11 therapy administered at our hospital had been rated as progressive disease (PD). The initial dose level of TS-1 was set at 80 mg/m2. The median follow-up period was 8 months. The response rate to TS-1 therapy was 14.3% (1/7). Four cases (57.1%) were rated as showing partial response (PR) or no change (NC). The median time to treatment failure (TTF) was 117 days. Thus, relatively satisfactory tumor dormancy was achieved in IFL-resistant cases. All adverse reactions observed were grade 2 or less severe. These results suggest that TS-1 used as the second/third-line therapy will contribute to improving the prognosis of patients with advanced or recurrent colorectal cancer.
Kabeshima
Yasuo
Y
Dept. of Surgery, Kasumigaura Medical Center.
Takahashi
Yoko
Y
Kameyama
Noriaki
N
Toizumi
Atsushi
A
Tamura
Yoichiro
Y
Kageyama
Takahisa
T
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010094:Oxonic Acid / Q000627:therapeutic use*; D011379:Prognosis; D011725:Pyridines / Q000627:therapeutic use*; D005641:Tegafur / Q000627:therapeutic use*
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D011725:Pyridines; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid